CALDAN Therapeutics, a spin-out company from the University of Glasgow and University of Southern Denmark, Caldan Therapeutics has announced key executive appointments and an exclusive collaboration with Sygnature Discovery, based in BioCity, Nottingham, UK.

Caldan, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes has named Dr Frank M Armstrong as non-executive chairman and Dr Philip Boyd as chief financial officer. Dr Gerry Thomas also joins as chief operating officer. Dr Stephen Connolly joins as vice president of drug discovery.

The Sygnature collaboration will see the provision of integrated drug discovery support to Caldan’s research projects in the metabolic disease area, enabling Caldan to access a broad range of skill sets to support its existing in-house research activities in Scotland and Denmark.